群多普利

C₂₄H₃₄N₂O₅

430.54

MFCD00865776

329826801

NA.77

Trandolapril has been used as an angiotensin-converting enzyme (ACE) inhibitor to study its effects on responsiveness of human retinal endothelial cells (HRECs) to vascular endothelial growth factor (VEGF).

Trandolapril is an ACE inhibitor. Trandolapril differs from other ACE inhibitors in that it has a longer biological half-life and a high degree of lipophilicity.
Studies have reported that trandolapril inhibits atherosclerosis¹ and decreases the occurrence of atrial fibrillation².

This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Trandolapril is soluble in DMSO at a concentration that is greater than or equal to 20 mg/ml.

Tandem Mass Spectrometry data independently generated by Scripps Center for Metabolomics is available to view or download in PDF. T4827.pdf Tested metabolites are featured on Scripps Center for Metabolomics METLIN Metabolite Database. To learn more, visit sigma.com/metlin.

100

≥98% (HPLC)

powder

white

DMSO: ≥20 mg/mL

Abbott

CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2C3CCCCC3C[C@H]2C(O)=O

1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1

VXFJYXUZANRPDJ-WTNASJBWSA-N

human ... ACE(1636)

10, 50 mg in glass bottle

GHS08

Danger

H360D

P201 - P202 - P280 - P308 + P313 - P405 - P501

Repr. 1B

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK 3

Eyeshields, Gloves, type N95 (US)